Fred Hutchinson Cancer Research Center - Recruiting 2 years or older. - A Randomized Phase II Study of Imatinib and Rituximab for Cutaneous Sclerosis After Allogeneic Hematopoietic Cell Transplantation.
Northwestern University - Recruiting 18 years to 60 years. - Randomized Study of Different Non-myeloablative Conditioning Regimens With Hematopoietic Stem Cell Support in Patients With Scleroderma (Autologous Systemic Sclerosis Immune Suppression Trial - II ASSIST-IIb).
Cytoxan rATG/Fludarabine regiment followed by SCT; cyclophosphamide regimen followed by SCT